0 CHECKOUT

Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016

  • ID: 586431
  • June 2016
  • Region: Global
  • 1389 Pages
  • CurrentPartnering
1 of 5

FEATURED COMPANIES

  • Abbott Japan
  • AstraZeneca
  • Cypress Bioscience
  • ImmunoGen
  • Nektar Therapeutics
  • Schering-Plough
  • MORE

The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2010 to 2016.

The report provides a detailed understanding and analysis of how and why companies enter M&A deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction.

Merger and acquisition is a constant activity within the biopharma sector. In the past, biopharma companies have sought to merge or acquire competitor companies in order to achieve critical mass both in R&D and sales and marketing, thus ensuring continued growth and dominance in a highly competitive and global marketplace.

In 1987, the largest ten companies were responsible for approximately twelve percent of global pharmaceutical sales. By 2002, this figure had become nearly fifty percent. This concentration was principally due to big pharma mega mergers.

The rewards READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Japan
  • AstraZeneca
  • Cypress Bioscience
  • ImmunoGen
  • Nektar Therapeutics
  • Schering-Plough
  • MORE

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2010
2.3.1. M&A dealmaking by year, 2010 to 2016
2.3.2. M&A dealmaking by industry sector, 2010 to 2016
2.3.3. M&A dealmaking by therapy area, 2010 to 2016
2.3.4. M&A dealmaking by most active company, 2010 to 2016
2.4. Key M&A trends
2.5. Option to acquire the new acquisition?
2.5.1. Case study 1: Cephalon - Ception
2.5.2. Case study 2: HertArt Aps - Vitrolife
2.6. When M&A can be useful
2.7. Attributes of M&A deals
2.7.1. M&A as an alternative to IPO
2.8. Partnering deals with M&A component
2.8.1. Partnering as a precursor to M&A
2.8.1.a. Case study 3: Celgene - VentiRx Pharmaceuticals
2.8.2. Equity as part of partnering deal
2.8.2.a. Case study 4: BioMarin - Catalyst Pharma Partners
2.8.2.b. Case study 5: Pfizer - Clovis Oncology
2.8.2.c. Case study 6: Tesaro - OPKO Health
2.8.3. Conversion of partnership to acquisition
2.8.4. But M&A is not always the route followed
2.9. Big pharma mega mergers - are we at the end of the road?
2.9.1. Growth of Johnson & Johnson through M&A
2.9.2. Growth of Novartis through M&A
2.10. Accessing innovation through M&A
2.10.1. Big pharma acquisitions of small companies
2.10.1.a. Case study 7: Abbott - Facet Biotechnology
2.10.1.b. Case study 8: Gilead Sceinces - Pharmasset
2.10.2. Medium and small biopharma - use of M&A
2.10.2.a. Case study 9: Allergan - MAP Pharmaceuticals
2.10.2.b. Case study 10: Reckitt Benckiser - Schiff Nutrition International
2.10.3. Using M&A to build a company
2.10.3.a. Case study 11: Shire - built from M&A
2.10.3.b. Case study 12: Zeneus - acquiring a ready-made European capability
2.10.3.c. Case study 13: Novartis - from pure pharma to half generic
2.10.4. Emergence of biotech-biotech mergers
2.10.4.a. Case study 14: Merger between Biogen and Idec
2.10.4.b. Case study 15: Amgen acquisition activity
2.11. The emerging role of private equity in M&A
2.12. Implementing M&A transactions
2.13. Joint ventures as alternative to M&A
2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.3.1. Example acquisition agreements
3.3.1.a. Case study 16: Allergan - SkinMedica
3.4. Acquisition as part of a wider alliance agreement
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 17: MGI Pharma - AkaRx
3.5. Merger agreements
3.5.1. Example merger agreements
3.5.1.a. Case study 18: Synergy Pharmaceuticals - Callisto Pharmaceuticals

Chapter 4 - Leading M&A deals

4.1. Introduction
4.2. Top M&A deals by value

Chapter 5 - Top 50 most active M&A dealmakers

5.1. Introduction
5.2. Top 50 most active M&A dealmakers

Chapter 6 - M&A contract directory 2010- 2016

6.1. Introduction
6.2. M&A deals with contracts 2010 to 2016

Appendices

Appendix 1 - M&A deals by company A-Z
Appendix 2 - M&A deals by industry sector
Appendix 3 - M&A deals by therapy area
Appendix 4 -Deal type definitions

About

TABLE OF FIGURES

Figure 1: Definition of merger and acquisition
Figure 2: Trends in M&A deal announcements, 2010 to 2016
Figure 3: MA& deals by industry sector, 2010 to 2016
Figure 4: M&A deals by therapy area, 2010 to 2016
Figure 5: Top 50 most active M&A dealmakers, 2010 to 2016
Figure 6: Key recent M&A trends - 2010 to present
Figure 7: Situations where M&A can prove useful
Figure 8: Recent partnering deals involving equity participation in the licensor
Figure 9: Equity investments converting to acquisitions
Figure 10: Johnson & Johnson’s growth through M&A
Figure 11: Novartis’s growth through M&A since 2000
Figure 12: Shire’s M&A history
Figure 13: Amgen’s biotech-biotech acquisition trail
Figure 14: Recent private equity M&A activity
Figure 15: Issues in implementing M&A agreements
Figure 16: Recent joint venture agreements
Figure 17: Recent joint ventures in the biopharma sector
Figure 18: Future trends in M&A in biopharma
Figure 19: Components of the acquisition deal structure
Figure 20: Components of the merger deal structure
Figure 21: Top M&A deals by value 2010 to 2016
Figure 22: Most active M&A dealmakers 2010 to 2016

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Abbott Japan
  • AstraZeneca
  • Cypress Bioscience
  • ImmunoGen
  • Nektar Therapeutics
  • Schering-Plough
  • MORE

Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 provides the reader with the following key benefits:

In-depth understanding of M&A deal trends since 2010
Analysis of the structure of M&A agreements with numerous real life case studies
Comprehensive access to over 2,200 actual M&A deals entered into by the world’s biopharma companies
Detailed access to actual M&A deals entered into by the leading fifty bigpharma companies
Insight into the terms included in a M&A agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 is intended to provide the reader with an in-depth understanding of the M&A trends and structure of deals entered into by leading biopharma companies worldwide.

Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 includes:

Trends in M&A dealmaking in the biopharma industry since 2010
Analysis of M&A deal structure
Case studies of real-life M&A deals
Access to over 2,200 M&A deal records
The leading M&A deals by value since 2010
Most active M&A dealmakers since 2010

In Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016, the available deals are listed by:

Company A-Z
Headline value
Industry sector

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Note: Product cover images may vary from those shown
4 of 5

Abbott Japan

Abbott Laboratories

Abraxis BioScience

ACADIA Pharmaceuticals

Acceleron Pharma

Achillion Pharmaceuticals

Adnexus Therapeutics

Adolor

AEterna Zentaris

Affymax

Agensys

Alfacell

Allergan

Ambit Biosciences

Amgen

Amylin Pharmaceuticals

Anacor Pharmaceuticals

Anesiva

Archemix

Ariad Pharmaceuticals

ArQule

Array Biopharma

ARYx Therapeutics

Astellas Pharma

AstraZeneca

Athersys

Atley Pharmaceuticals

Auriga Laboratories

Aventis

AVEO Pharmaceuticals

Barrier Therapeutics

Bayer

Biogen Idec

BioMarin Pharmaceuticals

BioMerieux

Biovail

Boehringer Ingelheim

Bristol-Myers Squibb

Cardiome Pharma

Celgene

Cell Genesys

Cepheid

ChemoCentryx

Cornerstone Biopharma

Cortex Pharmaceuticals

Critical Therapeutics

Cubist Pharmaceuticals

CV Therapeutics

Cypress Bioscience

Cytokinetics

Daiichi Sankyo

DepoMed

Dey Pharma

DoctorDirectory

DOR BioPharma

Dyax

Dynavax Technologies

Eisai

Eli Lilly

Enanta Pharmaceuticals

Endo Pharmaceuticals

Exelixis

Facet Biotechnology

Forest Laboratories

Forest Pharmaceuticals

Galderma

Genentech

Genzyme

Gilead Sciences

GlaxoSmithKline

GTx

Hyperion Therapeutics

ImmunoGen

Immunomedics

Impax Laboratories

Incyte

Inspire Pharmaceuticals

InterMune

InVentiv Health

Ipsen

Ironwood Pharmaceuticals

Janssen Research & Development

KaloBios Pharmaceuticals

La Jolla Pharmaceutical

Macrogenics

MAP Pharmaceuticals

Maxygen

Medivation

Menarini

Merck and Co

Merck KGaA

Merck Sharpe & Dohme

Merrimack Pharmaceuticals

Metabasis Therapeutics

Micromet

MiddleBrook Pharmaceutical

Millennium

Mylan Laboratories

Nektar Therapeutics

Novartis

Novartis Consumer Health

Novo Nordisk

Nycomed

OncoGenex Pharmaceuticals

Optimer Pharmaceuticals

Orexigen Therapeutics

Ortho Biotech

Par Pharmaceutical

PDL BioPharma

Pfizer

PhotoMedex

Procter & Gamble

Procter & Gamble Pharmaceuticals

Purdue Pharma

Regeneron Pharmaceuticals

Rib-X Pharmaceuticals

Roche

Sagent Pharmaceuticals

Salix Pharmaceuticals

Sanofi-Aventis

Sanofi-Pasteur

Sanofi

Santarus

Schering-Plough

Seattle Genetics

Serono

Sigma-Tau

Solvay

Somaxon Pharmaceuticals

Spectrum Pharmaceuticals

Strativa Pharmaceuticals

Sucampo Pharmaceuticals

Synta Pharmaceuticals

Takeda Pharmaceutical

TAP Pharmaceutical

Targacept

Tercica

Teva Pharmaceuticals

Tibotec

Transcept Pharmaceuticals

Ucyclyd Pharma

Valeant Pharmaceuticals

Veracyte

Vernalis

Vical

Victory Pharma

Warner Chilcott

Watson Pharmaceuticals

Wyeth

Xenoport

Zogenix

ZymoGenetics

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A copy of the report will be emailed to you and a copy will be shipped to you in CD ROM format. The Electronic copy is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.